SCHEMBL563101

SCHEMBL563101

O=S(=O)(O)CCCCCS(=O)(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.61
PTGS1 P23219 1/20 0.50
PDE4A P27815 1/20 0.50
LMNA P02545 1/20 0.50
SLC6A6 P31641 1/20 0.50
CYP2C19 P33261 1/20 0.50
BLM P54132 1/20 0.50
EPHX2 P34913 1/20 0.41
CA5A P35218 2/20 0.36
CA5B Q9Y2D0 2/20 0.36
FAAH O00519 2/20 0.35
TSHR P16473 2/20 0.31
CA2 P00918 2/20 0.31
CA1 P00915 1/20 0.31
NT5E P21589 1/20 0.31
CA4 P22748 1/20 0.31
CA6 P23280 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1271285 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL28813930 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL1270769 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL922126 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL563945 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL1270542 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL6692218 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL1270406 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL6695830 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL1270555 1.00 APP (0.61) APPPTGS1PDE4ALMNASLC6A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119439655-A Corrosion-resistant developing solution and preparation method and application thereof 上海戎洲芯科技有限公司 2025-02-14 CN claimed
US-11389782-B2 Molecularly imprinted polymer beads for extraction of lithium, mercury, and scandium 6th Wave Innovations Corp. (US) 2022-07-19 US claimed
CN-110139708-B Molecularly imprinted polymer beads for extracting lithium, mercury and scandium 第六波创新公司 2022-06-21 CN claimed
CN-110139708-A Molecularly imprinted polymer beads for extracting lithium, mercury and scandium 第六波创新公司 2019-08-16 CN claimed
EP-3113273-B1 LITHIUM ION SECONDARY BATTERY AUTOMOTIVE ENERGY SUPPLY CORP (JP) 2019-03-13 EP claimed
EP-3113247-B1 LITHIUM ION SECONDARY BATTERY AUTOMOTIVE ENERGY SUPPLY CORP (JP) 2018-11-21 EP claimed
EP-2579377-B1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME UBE INDUSTRIES (JP) 2014-09-03 EP claimed
EP-2280036-B1 METHOD FOR PRODUCING ALIPHATIC POLYESTER RESIN, AND AN ALIPHATIC POLYESTER RESIN COMPOSITION TORAY INDUSTRIES (JP) 2013-11-13 EP claimed
US-20110002875-A1 METHOD FOR TREATING AMYLOIDOSIS BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2011-01-06 US claimed
US-20080317834-A1 Compounds and methods for modulating cerebral amyloid angiopathy NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2008-12-25 US claimed
WO-2001085093-A2 COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY NEUROCHEM, INC. (US) 2001-11-15 WO claimed
EP-1077690-A1 USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH Neurochem, Inc. (CA) 2001-02-28 EP claimed
EP-1064013-A1 $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES University of Washington (US) 2001-01-03 EP claimed
WO-1999045947-A9 IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIV WASHINGTON (US) 2000-03-02 WO claimed
WO-1999059571-A1 USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH NEUROCHEM, INC. (US) 1999-11-25 WO claimed
WO-1999045947-A1 IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIVERSITY OF WASHINGTON (US) 1999-09-16 WO claimed
US-5840294-A INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE QUEEN'S UNIVERSITY AT KINGSTON (CA) 1998-11-24 US claimed
EP-0814842-A1 METHOD FOR TREATING AMYLOIDOSIS Queen's University at Kingston (CA) 1998-01-07 EP claimed
US-5643562-A ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES QUEEN'S UNIVERSITY OF KINGSTON (CA) 1997-07-01 US claimed
WO-1996028187-A1 METHOD FOR TREATING AMYLOIDOSIS QUEEN'S UNIVERSITY AT KINGSTON (CA) 1996-09-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080317834-A1 Compounds and methods for modulating cerebral amyloid angiopathy APP, PYGB, MAPT APP 1/4885PTGS1 620/4885PDE4A 295/4885
US-20110002875-A1 METHOD FOR TREATING AMYLOIDOSIS TTR, IAPP, APP APP 3/4885PTGS1 3896/4885PDE4A 4579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.